Wegovy is an advanced form of Semaglutide GLP-1 thats specifically designed for weight loss
Addressing depression and obesity simultaneously, with two medications that work through complementary mechanisms and do not interfere with each other pharmacologically, represents one of the more elegant treatment combinations available today
As a GLP-1 receptor agonist, semaglutide mimics a hormone that targets areas of the brain involved in managing appetite
The side effect profiles differ between semaglutide and tirzepatide , so switching medications is sometimes the solution
demonstrated that the suppression of hypothalamic toll-like receptor 4 (TLR4) inflammatory signaling and the alleviation of endoplasmic reticulum (ER) stress are closely associated with the restoration of central leptin sensitivity
It does not factor in metabolic health markers like insulin resistance, inflammation, or cardiovascular risk